venetoclax

aml_84999

decitabine

clofarabine

plerixafor

breakthrough infection

quizartinib

patients acute myeloid

New England Journal of Medicine

Ivosidenib and azacitidine showed significant clinical benefit as compared with placebo and azacitidine in this difficult-to-treat population. Febrile neutropenia and infections were less frequent in the ivosidenib-and-azacitidine group than in the placebo-and-azacitidine group, whereas neutropenia and bleeding were more frequent in the ivosidenib-and-azacitidine group. (Funded by Agios Pharmaceuticals and Servier Pharmaceuticals; AGILE ClinicalTrials.gov number, NCT03173248.).

Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia